What happened with ALT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Altimmune is a late clinical-stage biopharmaceutical company whose business centers on pemvidutide, its lead experimental drug. It is developing the drug for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease. Pemvidutide acts on glucagon and GLP-1 receptors, targeting liver processes as well as appetite and craving. It has completed Phase 2 development, and Altimmune plans to move into Phase 3.
Altimmune has no approved products; almost all revenue to date has come from past government grants and contracts, rather than drug sales. It funds development through share sales and borrowing and seeks partners for late-stage development and commercialization. Its cash resources are insufficient to fund the trials needed to seek marketing approval and bring its candidates to market. The business therefore depends heavily on pemvidutide's progress and further funding or partnerships. Altimmune cannot sell its candidates as medicines without regulatory approval based on evidence of safety and effectiveness.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Altimmune's prospects hinge on pemvidutide showing distinct clinical benefits in liver disease, including against privately held Boehringer Ingelheim's competing GLP-1/glucagon dual agonist.
Madrigal Pharmaceuticals already sells Rezdiffra for MASH, setting a commercial benchmark for the liver-disease market Altimmune hopes to enter with pemvidutide. Watch Rezdiffra's U.S. net product revenue, which reached $958.4 million in 2025, as a measure of sales in that market.
Novo Nordisk's approved Wegovy treatment for MASH and investigational liver medicines compete with Altimmune's pemvidutide. Watch Wegovy's use in MASH patients with moderate to advanced liver fibrosis and the clinical progress of Novo Nordisk's liver pipeline, rather than its broader diabetes business.
Viking Therapeutics is developing an oral MASH medicine that activates the thyroid hormone receptor beta, competing for the same treatment market as Altimmune's pemvidutide. Its MASH trial progress is the relevant signal; Viking had not generated revenue through the reporting period.
Inventiva concentrates on lanifibranor for MASH, the principal liver-disease market Altimmune targets with pemvidutide. Lanifibranor is Inventiva's only drug candidate in development after it stopped unrelated research in June 2025, making that program's clinical progress the news to watch.
Sagimet Biosciences is developing denifanstat for the same MASH patients Altimmune aims to treat with pemvidutide. Watch denifanstat's efficacy, safety and tolerability results, which help define what pemvidutide must compete against.
Eli Lilly is developing MASH medicines that activate two or three receptors, challenging the efficacy and differentiation of Altimmune's pemvidutide. Watch their liver-disease results against Altimmune's claim that pemvidutide's balanced glucagon and GLP-1 activity distinguishes it.
Aligos Therapeutics is developing an oral MASH medicine that activates the thyroid hormone receptor beta, competing with Altimmune's pemvidutide. Its MASH clinical progress matters more for this comparison than its reported revenue, which comes from collaborations and customers paying for research and development services.
GSK's investigational treatments for MASH and alcohol-related liver disease overlap with two of Altimmune's pemvidutide programs. Watch its FGF-21 medicines for MASH and GSK4532990 for alcohol-related liver disease, rather than its overall medicine and vaccine sales.
Adial Pharmaceuticals focuses on AD04 for alcohol use disorder, competing with Altimmune's pemvidutide program for that condition. Watch AD04's clinical results in the specific genetic subgroups identified by its companion diagnostic; Adial has no approved products for sale.
GSK plc earningsGSK
GSK’s report will show whether its FGF-21 MASH medicines and GSK4532990 for alcohol-related liver disease are advancing in markets where Altimmune is developing pemvidutide.
Look for clinical progress and results on these liver-disease programs, not GSK’s overall medicine sales. Advancing programs with persuasive findings would make competition for the same patients more concrete for Altimmune; limited progress would mean less evidence of near-term pressure from these candidates.
Fed Interest Rate Decision
For Altimmune, the Fed’s rate decision signals whether borrowing costs may rise or fall; if prime lifts the rate on its term loan, more cash goes to interest and less is available for clinical development.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could lift prime and increase interest on Altimmune’s term loan, leaving less cash for its pemvidutide trials and other clinical development.
If it comes in below expectations
Lower rates could ease pressure on prime and reduce interest on Altimmune’s term loan, leaving more cash available for pemvidutide trials and other clinical development.
Madrigal Pharmaceuticals, Inc. earningsMDGL
Madrigal Pharmaceuticals’ report will show Rezdiffra’s U.S. net product revenue, a commercial benchmark for Altimmune’s hoped-for entry into the MASH market with pemvidutide.
Watch whether Rezdiffra’s U.S. net product revenue continues to grow, using sales of this approved MASH medicine to gauge market demand. Growth would show that an existing treatment can generate sales in the market, giving Altimmune a commercial demand benchmark; flat or falling revenue would caution against assuming pemvidutide could quickly find buyers simply because the market exists.
Altimmune, Inc. earningsThis company
Altimmune has no approved products or product-sale revenue, so its report will show whether cash and trial spending can carry pemvidutide toward its next development stage.
Read research and development spending alongside cash used in operations, and look for reported progress in trials for MASH, alcohol-related liver disease and alcohol use disorder. Spending that supports trial progress, with cash to fund the next stage, would show development advancing; lower spending without corresponding progress, or mounting cash pressure, would leave later-stage trials dependent on new financing or a partner.
